CSIMarket
 
Adc Therapeutics Sa  (NYSE: ADCT)
 

Adc Therapeutics Sa's Suppliers Performance

ADCT's Supply Chain




 
ADCT Costs vs Sales of Suppliers Growth Adc Therapeutics Sa's cost of sales deteriorated by -56.15 % year on year, relative to one quarter ago cost of sales fell by -88.39 % in Q2.

More on ADCT Suppliers



Adc Therapeutics Sa's cost of sales deteriorated by -56.15 % year on year, compare to one quarter ago cost of sales fell by -88.39 % in Q2.

More on ADCT Suppliers




Adc Therapeutics Sa's Comment on Supply Chain


The company depends on raw materials, components, and finished products, many of which are sourced from sole suppliers and contract manufacturing organizations (CMOs) for production. Its products and candidates incorporate highly potent cytotoxins, payloads, and complex conjugation technologies that require specialized manufacturing and handling. The company faces risks related to contamination, liability, compliance with environmental and safety regulations, and increased costs of components or raw materials. Supply interruptions, particularly from sole source suppliers, could disrupt manufacturing processes and raise costs. Additionally, biologically derived raw materials are challenging to procure and may be subject to contamination or recall, potentially affecting development timelines and business outcomes.

Adc Therapeutics Sa's Comment on Supply Chain


The company depends on raw materials, components, and finished products, many of which are sourced from sole suppliers and contract manufacturing organizations (CMOs) for production. Its products and candidates incorporate highly potent cytotoxins, payloads, and complex conjugation technologies that require specialized manufacturing and handling. The company faces risks related to contamination, liability, compliance with environmental and safety regulations, and increased costs of components or raw materials. Supply interruptions, particularly from sole source suppliers, could disrupt manufacturing processes and raise costs. Additionally, biologically derived raw materials are challenging to procure and may be subject to contamination or recall, potentially affecting development timelines and business outcomes.







ADCT's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Adc Therapeutics Sa 162.77 79.58 -96.91 193
SUBTOTAL 0.00 0.00 0.00 -


Sources: Adc Therapeutics Sa's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Adc Therapeutics Sa’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.